TuisAGIO • NASDAQ
add
Agios Pharmaceuticals Inc
Vorige sluiting
$34,42
Dagwisseling
$33,79 - $34,06
Jaarwisseling
$20,96 - $62,58
Markkapitalisasie
1,94Â mjd USD
Gemiddelde volume
1,09Â m
P/V-verhouding
2,97
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 8,96Â m | 21,15% |
Bedryfskoste | 38,54Â m | 49,24% |
Netto inkomste | 947,92Â m | 1Â 137,97% |
Netto winsgrens | 10,57Â k | 956,76% |
Wins per aandeel | -1,47 | 10,66% |
EBITDA | -101,47Â m | -2,21% |
Effektiewe belastingkoers | 5,31% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,00Â mjd | 55,18% |
Totale bates | 1,79Â mjd | 77,89% |
Totale aanspreeklikheid | 165,12Â m | 37,13% |
Totale ekwiteit | 1,63 mjd | — |
Uitstaande aandele | 57,03 m | — |
Prys om te bespreek | 1,21 | — |
Opbrengs op bates | -20,04% | — |
Opbrengs op kapitaal | -21,31% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 947,92Â m | 1Â 137,97% |
Kontant van bedrywe | -84,22Â m | -36,62% |
Kontant van beleggings | 250,79Â m | 537,49% |
Kontant van finansiering | 2,64Â m | 40,12% |
Netto kontantverandering | 169,21Â m | 928,66% |
Beskikbare kontantvloei | -3,03Â m | 95,64% |
Meer oor
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Gestig
2008
Webwerf
Werknemers
385
